Australian researchers emphasize that therapies that inhibit the formation and accumulation of advanced glycation end-products (AGEs) or that “remove established AGE modifications” will be an important part of treating diabetics with kidney problems.
AGEs are caused by chronic high blood glucose and oxidative stress in diabetes.
“In particular, AGEs appear to have a key role in diabetic nephropathy,” they write. “Their importance as downstream mediators of tissue injury in diabetic kidney disease is demonstrated by animal studies using inhibitors of advanced glycation to retard the development of nephropathy without directly influencing glycemic control.”
—American Journal of Therapeutics, November-December 2005